{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:06:48Z","timestamp":1790946408938,"version":"4.1.0"},"reference-count":120,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by reduced circulating levels and\/or impaired function of alpha-1 antitrypsin (AAT), a key serine protease inhibitor, in which loss of effective antiprotease protection results in unchecked neutrophil elastase activity and progressive lung tissue destruction. Although AATD accounts for approximately 1% of chronic obstructive pulmonary disease (COPD) cases and up to 2% of emphysema, AATD-related COPD remains largely underdiagnosed, despite guideline recommendations for systematic evaluation in patients with COPD, particularly in high-risk clinical settings. Pathologically, AATD-related COPD is not limited to the typical early-onset, lower-lobe-predominant emphysema, also including upper-lobe or mixed emphysema patterns, airway-predominant disease, small airways dysfunction, and bronchiectasis. Clinically, AATD-related COPD is distinguished from smoking-related COPD by its earlier onset, physiological impairment that is often disproportionate to smoking exposure, and its potential presence of certain extrapulmonary manifestations. Diagnosis and monitoring are also challenged by the frequent discordance between airflow limitation and gas transfer impairment, as well as the early involvement of small airways, limiting reliance on spirometry alone. A multimodal assessment incorporating more sensitive functional techniques and CT densitometry may provide a more precise evaluation of disease burden, progression, and prognosis. Management generally follows standard COPD principles, with intravenous AAT augmentation therapy remaining currently the only established disease-modifying therapy for selected patients with severe deficiency. The advent of new pharmacological and gene-based therapies emphasizes the importance of developing personalized management strategies that integrate genotype and longitudinal disease behavior. This narrative review summarizes current evidence on AATD-associated COPD, focusing on its genetic basis and pathophysiological features, clinical and functional heterogeneity, current and emerging diagnostic and monitoring approaches, and disease-specific management considerations.<\/jats:p>","DOI":"10.3390\/medicina62040639","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:33:33Z","timestamp":1774622013000},"page":"639","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4456-8987","authenticated-orcid":false,"given":"Evangelia","family":"Fouka","sequence":"first","affiliation":[{"name":"2nd Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 124 62 Rimini, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4549-7495","authenticated-orcid":false,"given":"Argyro","family":"Vrouvaki","sequence":"additional","affiliation":[{"name":"2nd Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 124 62 Rimini, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Moustaka Christodoulou","sequence":"additional","affiliation":[{"name":"2nd Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 124 62 Rimini, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-9922","authenticated-orcid":false,"given":"Stelios","family":"Loukides","sequence":"additional","affiliation":[{"name":"2nd Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 124 62 Rimini, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Hillas","sequence":"additional","affiliation":[{"name":"2nd Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 124 62 Rimini, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1513\/AnnalsATS.201507-468KV","article-title":"Well-Known and Less Well-Known Functions of Alpha-1 Antitrypsin. Its Role in Chronic Obstructive Pulmonary Disease and Other Disease Developments","volume":"13","author":"Janciauskiene","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1042\/CS20080484","article-title":"alpha1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies","volume":"116","author":"Ekeowa","year":"2009","journal-title":"Clin. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1172-6-14","article-title":"Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema","volume":"6","author":"Blanco","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","first-page":"132","article-title":"The Electrophoretic \u03b1;1-Globulin Pattern of Serum in \u03b1;1-Antitrypsin Deficiency","volume":"15","author":"Laurell","year":"1963","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1081\/COPD-120028703","article-title":"What we owe to alpha(1)-antitrypsin and to Carl-Bertil Laurell","volume":"1","author":"Carrell","year":"2004","journal-title":"COPD"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0954-6111(98)90278-5","article-title":"Alpha 1-antitrypsin deficiency in Europe: Geographical distribution of Pi types S and Z","volume":"92","author":"Hutchison","year":"1998","journal-title":"Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1753465812457113","article-title":"Prevalence of \u03b11-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: A comprehensive review","volume":"6","author":"Blanco","year":"2012","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12931-022-02275-4","article-title":"Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry","volume":"23","author":"Miravitlles","year":"2022","journal-title":"Respir. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108278","DOI":"10.1016\/j.rmed.2025.108278","article-title":"Characterisation of patients with Alpha-1 antitrypsin deficiency using unsupervised machine learning tools","volume":"247","author":"Miravitlles","year":"2025","journal-title":"Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1164\/rccm.202106-1404OC","article-title":"Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease","volume":"205","author":"Ghosh","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104170","DOI":"10.1016\/j.lpm.2023.104170","article-title":"Alpha1-antitrypsin deficiency: An updated review","volume":"52","author":"Mornex","year":"2023","journal-title":"Presse Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2501101","DOI":"10.1183\/13993003.01101-2025","article-title":"A cure for alpha-1? Novel therapeutics in alpha-1 antitrypsin deficiency","volume":"66","author":"Alluhibi","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/TACG.S257511","article-title":"Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum","volume":"14","author":"Seixas","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20406223211015954","DOI":"10.1177\/20406223211015954","article-title":"Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency","volume":"12","author":"Foil","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Voynow, J.A., and Shinbashi, M. (2021). Neutrophil Elastase and Chronic Lung Disease. Biomolecules, 11.","DOI":"10.3390\/biom11081065"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3892\/mmr.2025.13472","article-title":"\u03b1-1 Antitrypsin is a potential target of inflammation and immunomodulation (Review)","volume":"31","author":"Wang","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104177","DOI":"10.1016\/j.cellimm.2020.104177","article-title":"Distinct anti-inflammatory properties of alpha1-antitrypsin and corticosteroids reveal unique underlying mechanisms of action","volume":"356","author":"Schuster","year":"2020","journal-title":"Cell. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.rmed.2008.01.009","article-title":"Alpha-1 antitrypsin Null mutations and severity of emphysema","volume":"102","author":"Fregonese","year":"2008","journal-title":"Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1700610","DOI":"10.1183\/13993003.00610-2017","article-title":"European Respiratory Society statement: Diagnosis and treatment of pulmonary disease in \u03b1(1)-antitrypsin deficiency","volume":"50","author":"Miravitlles","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"200014","DOI":"10.1183\/16000617.0014-2020","article-title":"Prevalence of \u03b1(1)-antitrypsin PiZZ genotypes in patients with COPD in Europe: A systematic review","volume":"29","author":"Blanco","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMra1910234","article-title":"Alpha(1)-Antitrypsin Deficiency","volume":"382","author":"Strnad","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1378\/chest.125.5.1952","article-title":"Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant","volume":"125","author":"Mulgrew","year":"2004","journal-title":"Chest"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1164\/rccm.201308-1458OC","article-title":"Z \u03b11-antitrypsin confers a proinflammatory phenotype that contributes to chronic obstructive pulmonary disease","volume":"189","author":"Alam","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2024.10.010","article-title":"Longitudinal Evaluation of Individuals with Severe Alpha-1 Antitrypsin Deficiency (Pi\u2217ZZ Genotype)","volume":"168","author":"Loomba","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27258","DOI":"10.1016\/S0021-9258(19)61505-X","article-title":"Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity","volume":"275","author":"Taggart","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.79.6.2041","article-title":"Potential mechanism of emphysema: Alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity","volume":"79","author":"Carp","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/thoraxjnl-2015-206906","article-title":"PiSZ alpha-1 antitrypsin deficiency (AATD): Pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD","volume":"70","author":"Green","year":"2015","journal-title":"Thorax"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1164\/rccm.202002-0262OC","article-title":"Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency","volume":"202","author":"Franciosi","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1164\/rccm.201311-1984OC","article-title":"Clarification of the risk of chronic obstructive pulmonary disease in \u03b11-antitrypsin deficiency PiMZ heterozygotes","volume":"189","author":"Molloy","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7163-3_1","article-title":"Pathophysiology of Alpha-1 Antitrypsin Deficiency Liver Disease","volume":"1639","author":"Teckman","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12931-021-01842-5","article-title":"Association between circulating alpha-1 antitrypsin polymers and lung and liver disease","volume":"22","author":"Belmonte","year":"2021","journal-title":"Respir. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"210262","DOI":"10.1183\/16000617.0262-2021","article-title":"Disease burden associated with alpha-1 antitrypsin deficiency: Systematic and structured literature reviews","volume":"31","author":"Miravitlles","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/15412555.2021.1917532","article-title":"Alpha-1 Antitrypsin Deficiency-Associated Clinical Manifestations and Healthcare Resource Use in the United States","volume":"18","author":"Herrera","year":"2021","journal-title":"COPD"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/COPD.S195847","article-title":"Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency","volume":"14","author":"Hiller","year":"2019","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1164\/rccm.200703-489OC","article-title":"Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency","volume":"176","author":"Parr","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1183\/09031936.05.00021605","article-title":"alpha1-Antitrypsin deficiency and lung disease: Risk modification by occupational and environmental inhalants","volume":"26","author":"Senn","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_37","first-page":"280","article-title":"Why is Disease Penetration so Variable in Alpha-1 Antitrypsin Deficiency? The Contribution of Environmental Factors","volume":"7","author":"Rangaraju","year":"2020","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17534666251318841","DOI":"10.1177\/17534666251318841","article-title":"Advancing the understanding and treatment of lung pathologies associated with alpha 1 antitrypsin deficiency","volume":"19","author":"Turner","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1164\/rccm.200406-761OC","article-title":"Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment","volume":"170","author":"Parr","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/15412550802522320","article-title":"Phenotypic differences in alpha 1 antitrypsin-deficient sibling pairs may relate to genetic variation","volume":"5","author":"Wood","year":"2008","journal-title":"COPD"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.rmed.2012.12.003","article-title":"Age related development of respiratory abnormalities in non-index \u03b1-1 antitrypsin deficient studies","volume":"107","author":"Holme","year":"2013","journal-title":"Respir. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2147\/COPD.S111508","article-title":"Individualized lung function trends in alpha-1-antitrypsin deficiency: A need for patience in order to provide patient centered management?","volume":"11","author":"Stockley","year":"2016","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/15412555.2015.1021909","article-title":"The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency","volume":"12","author":"Piitulainen","year":"2015","journal-title":"COPD"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1183\/09031936.00104712","article-title":"Clinical phenotypes of Italian and Spanish patients with \u03b11-antitrypsin deficiency","volume":"42","author":"Piras","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2147\/COPD.S155226","article-title":"Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT)","volume":"13","author":"Esquinas","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1378\/chest.13-1886","article-title":"Spirometric and gas transfer discordance in a \u03b11 -antitrypsin deficiency. patient characteristics and progression","volume":"145","author":"Ward","year":"2014","journal-title":"Chest"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1183\/09031936.00061208","article-title":"Rate of progression of lung function impairment in alpha1-antitrypsin deficiency","volume":"33","author":"Dawkins","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/thx.2005.054890","article-title":"Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency","volume":"61","author":"Parr","year":"2006","journal-title":"Thorax"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMoa1106955","article-title":"Small-airway obstruction and emphysema in chronic obstructive pulmonary disease","volume":"365","author":"McDonough","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/thx.52.3.244","article-title":"Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ)","volume":"52","author":"Piitulainen","year":"1997","journal-title":"Thorax"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1602055","DOI":"10.1183\/13993003.02055-2016","article-title":"Maximal mid-expiratory flow detects early lung disease in \u03b1(1)-antitrypsin deficiency","volume":"49","author":"Stockley","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"107222","DOI":"10.1016\/j.rmed.2023.107222","article-title":"Small airways disease in patients with alpha-1 antitrypsin deficiency","volume":"211","author":"Toumpanakis","year":"2023","journal-title":"Respir. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1378\/chest.117.2.415","article-title":"Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis","volume":"117","author":"Cuvelier","year":"2000","journal-title":"Chest"},{"key":"ref_54","first-page":"145","article-title":"The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry","volume":"6","author":"Eden","year":"2019","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.2147\/COPD.S271810","article-title":"The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD\/Emphysema, Asthma and Bronchiectasis","volume":"15","author":"Veith","year":"2020","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1148\/radiology.199.1.8633137","article-title":"Alpha 1-antitrypsin deficiency: Evaluation of bronchiectasis with CT","volume":"199","author":"King","year":"1996","journal-title":"Radiology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13023-023-02830-2","article-title":"The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: Initial report of EARCO","volume":"18","author":"Stockley","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/thoraxjnl-2019-214195","article-title":"Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis","volume":"75","author":"Carreto","year":"2020","journal-title":"Thorax"},{"key":"ref_59","first-page":"1","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2501126","DOI":"10.1183\/13993003.01126-2025","article-title":"European Respiratory Society clinical practice guideline for the management of adult bronchiectasis","volume":"66","author":"Chalmers","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17476348.2020.1804364","article-title":"Endo-phenotyping of COPD patients","volume":"15","author":"Barnes","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.1513\/AnnalsATS.201609-718AW","article-title":"Telomerase and the Genetics of Emphysema Susceptibility. Implications for Pathogenesis Paradigms and Patient Care","volume":"13","author":"Stanley","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2040622321995691","DOI":"10.1177\/2040622321995691","article-title":"The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency","volume":"12","author":"Tejwani","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"American Thoracic Society, and European Respiratory Society (2003). American Thoracic Society\/European Respiratory Society statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am. J. Respir. Crit. Care Med., 168, 818\u2013900.","DOI":"10.1164\/rccm.168.7.818"},{"key":"ref_65","unstructured":"(2025, January 01). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. (GOLD). Available online: https:\/\/goldcopd.org\/2025-gold-report\/."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/15412555.2020.1812055","article-title":"PredictAAT: Accounting for Inflammation in the Diagnosis of Alpha 1 Antitrypsin Deficiency","volume":"17","author":"Kueppers","year":"2020","journal-title":"COPD"},{"key":"ref_67","first-page":"33","article-title":"Alpha-1 antitrypsin protease inhibitor typing in immobilized pH gradients","volume":"23","author":"Drobnies","year":"1993","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2147\/COPD.S224221","article-title":"Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR\/Luminescence-Based Technology","volume":"14","author":"Veith","year":"2019","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jmoldx.2015.07.002","article-title":"SERPINA1 Full-Gene Sequencing Identifies Rare Mutations Not Detected in Targeted Mutation Analysis","volume":"17","author":"Graham","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pulmoe.2022.12.007","article-title":"Alpha1-antitrypsin deficiency in Greece: Focus on rare variants","volume":"30","author":"Papiris","year":"2024","journal-title":"Pulmonology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.chest.2017.11.017","article-title":"The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency","volume":"153","author":"Campos","year":"2018","journal-title":"Chest"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1753465815602162","article-title":"Alpha-1-antitrypsin deficiency: Increasing awareness and improving diagnosis","volume":"10","author":"Greulich","year":"2016","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0140-6736(15)60860-1","article-title":"Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): A randomised, double-blind, placebo-controlled trial","volume":"386","author":"Chapman","year":"2015","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(16)30430-1","article-title":"Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: An open-label extension trial (RAPID-OLE)","volume":"5","author":"McElvaney","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.rmed.2015.01.022","article-title":"SPARTA clinical trial design: Exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency","volume":"109","author":"Sorrells","year":"2015","journal-title":"Respir. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1513\/AnnalsATS.202211-954OC","article-title":"Impact of a Computerized Clinical Decision Support System to Improve Chronic Obstructive Pulmonary Disease Diagnosis and Testing for Alpha-1 Antitrypsin Deficiency","volume":"20","author":"Campos","year":"2023","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"190073","DOI":"10.1183\/16000617.0073-2019","article-title":"\u03b1(1)-Antitrypsin deficiency and chronic respiratory disorders","volume":"29","author":"Cazzola","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/thx.2003.006510","article-title":"Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history","volume":"59","author":"Needham","year":"2004","journal-title":"Thorax"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Karado\u011fan, D., Torres-Duran, M., Tanash, H., Rodr\u00edguez-Garc\u00eda, C., Jensen, J.S., Corsico, A.G., L\u00f3pez-Campos, J.L., Chapman, K., Clarenbach, C., and Guimaraes, C. (2025). Clinical characteristics of AATD-related COPD patients vary with age at diagnosis: Data from the EARCO international registry. BMC Pulm. Med., 25.","DOI":"10.1186\/s12890-025-03782-y"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.4081\/monaldi.2021.1883","article-title":"Z-alpha1-antitrypsin polymers and small airways disease: A new paradigm in alfa-1 anti-trypsin deficiency-related COPD development?","volume":"91","author":"Pini","year":"2021","journal-title":"Monaldi Arch. Chest Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/17476348.2024.2380070","article-title":"Small airways disease in chronic obstructive pulmonary disease","volume":"18","author":"Lazarinis","year":"2024","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ellis, P., Parekh, G., Duvoix, A., Watson, L., Sharp, A., Mobeen, F., Pye, A., Stockley, R., and Turner, A. (2024). Characteristics of alpha-1 antitrypsin deficiency related lung disease exacerbations using a daily symptom diary and urinary biomarkers. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0297125"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.2147\/COPD.S276773","article-title":"Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency","volume":"15","author":"Sandhaus","year":"2020","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_84","first-page":"789","article-title":"Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD","volume":"7","author":"Vijayasaratha","year":"2012","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000119718","article-title":"Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD","volume":"76","author":"Corda","year":"2008","journal-title":"Respiration"},{"key":"ref_86","first-page":"121","article-title":"Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease Patients with Underlying Alpha-1 Antitrypsin Deficiency: A Systematic Review and Practical Recommendations","volume":"11","author":"Alwadani","year":"2024","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"20406223211002988","DOI":"10.1177\/20406223211002988","article-title":"Lung and liver transplantation in patients with alpha-1 antitrypsin deficiency","volume":"12","author":"Zamora","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM198704233161704","article-title":"Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema","volume":"316","author":"Wewers","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"(1998). Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am. J. Respir. Crit. Care Med., 158, 49\u201359.","DOI":"10.1164\/ajrccm.158.1.9712017"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1517\/14712598.2012.676638","article-title":"A review of augmentation therapy for alpha-1 antitrypsin deficiency","volume":"12","author":"Mohanka","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1183\/09031936.00159408","article-title":"Exploring the role of CT densitometry: A randomised study of augmentation therapy in alpha1-antitrypsin deficiency","volume":"33","author":"Dirksen","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1164\/rccm.202305-0863OC","article-title":"Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis","volume":"208","author":"Fraughen","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_93","first-page":"1196","article-title":"Mortality in individuals with severe deficiency of alpha1-antitrypsin: Findings from the National Heart, Lung, and Blood Institute Registry","volume":"127","author":"Stoller","year":"2005","journal-title":"Chest"},{"key":"ref_94","first-page":"139","article-title":"Quality of Life and Mortality Outcomes for Augmentation Na\u00efve and Augmented Patients with Severe Alpha-1 Antitrypsin Deficiency","volume":"10","author":"Ellis","year":"2023","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1378\/chest.08-1129","article-title":"Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years","volume":"135","author":"Campos","year":"2009","journal-title":"Chest"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e036045","DOI":"10.1136\/bmjopen-2019-036045","article-title":"Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: Initial report of a centralised database of the NIHR rare diseases translational research collaborative","volume":"10","author":"Crossley","year":"2020","journal-title":"BMJ Open"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/thorax.58.12.1020","article-title":"Predictors of mortality in alpha1-antitrypsin deficiency","volume":"58","author":"Dawkins","year":"2003","journal-title":"Thorax"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2147\/TCRM.S234377","article-title":"Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives","volume":"16","author":"Quinn","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_99","first-page":"6","article-title":"Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States","volume":"6","author":"Sieluk","year":"2018","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1164\/rccm.201901-0010OC","article-title":"The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial","volume":"200","author":"Campos","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/15412555.2012.758698","article-title":"Inhaled alpha 1-antitrypsin: Gauging patient interest in a new treatment","volume":"10","author":"Monk","year":"2013","journal-title":"COPD"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1185\/030079905X46395","article-title":"A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products","volume":"21","author":"Cowden","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"206","DOI":"10.7326\/0003-4819-111-3-206","article-title":"Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin","volume":"111","author":"Hubbard","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_104","first-page":"744","article-title":"Inhalation of [123I]alpha1-protease inhibitor: Toward a new therapeutic concept of alpha1-protease inhibitor deficiency?","volume":"42","author":"Kropp","year":"2001","journal-title":"J. Nucl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1900673","DOI":"10.1183\/13993003.00673-2019","article-title":"Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD","volume":"54","author":"Stolk","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_106","unstructured":"(2025, January 01). Health NIo. Evaluate Efficacy and Safety of \u201cKamada-AAT for Inhalation\u201d in Patients with AATD (InnovAATe) 2019, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04204252."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1073\/pnas.97.4.1796","article-title":"Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency","volume":"97","author":"Burrows","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_108","first-page":"34","article-title":"Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: A preliminary study","volume":"39","author":"Teckman","year":"2004","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1126\/science.1190354","article-title":"An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis","volume":"329","author":"Hidvegi","year":"2010","journal-title":"Science"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/15412555.2013.764978","article-title":"Gene-based therapy for alpha-1 antitrypsin deficiency","volume":"10","author":"Mueller","year":"2013","journal-title":"COPD"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"16363","DOI":"10.1073\/pnas.0904514106","article-title":"Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy","volume":"106","author":"Brantly","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/hum.2011.053","article-title":"Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing \u03b11-antitrypsin: Interim results","volume":"22","author":"Flotte","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1097\/MS9.0000000000003393","article-title":"Fazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease findings from the SEQUOIA phase 2 trial","volume":"87","author":"Liaquat","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/13543784.2023.2239707","article-title":"RNAi therapeutics for diseases involving protein aggregation: Fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease","volume":"32","author":"Strnad","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_115","unstructured":"Ltd, W.L.S. (2025, January 01). A Phase 1b\/2a Open-Label Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of WVE-006 in Participants with Alpha-1 Antitrypsin Deficiency Pi*ZZ (RestorAATion-2), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06405633."},{"key":"ref_116","unstructured":"Korro Bio, I. (2025, January 01). A Phase 1\/2a, Single- and Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO-110 in Healthy Adult Volunteers and in Adult Participants with Alpha-1 Antitrypsin Deficiency (REWRITE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06677307."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1089\/hum.2017.227","article-title":"Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice","volume":"29","author":"Shen","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"690","DOI":"10.4187\/respcare.05933","article-title":"Anti-Proteases and Alpha-1 Antitrypsin Augmentation Therapy","volume":"63","author":"Strange","year":"2018","journal-title":"Respir. Care"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2501019","DOI":"10.1183\/13993003.01019-2025","article-title":"Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiency","volume":"66","author":"Wells","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"20406223211010172","DOI":"10.1177\/20406223211010172","article-title":"Management of lung disease in alpha-1 antitrypsin deficiency: What we do and what we do not know","volume":"12","author":"Barjaktarevic","year":"2021","journal-title":"Ther. Adv. Chronic Dis."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/639\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:12:48Z","timestamp":1774624368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":120,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["medicina62040639"],"URL":"https:\/\/doi.org\/10.3390\/medicina62040639","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}